Symbols / ELDN Stock $3.84 +7.26% Eledon Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
ELDN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 296.40M
Enterprise Value 185.87M
Income -78.15M
Sales —
FCF (ttm) -39.67M
Book/sh 1.32
Cash/sh 1.44
Employees 33
Insider 10d —
IPO Sep 17, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.31
PEG —
P/S —
P/B 2.90
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 8.30
Current Ratio 8.44
Debt/Eq 0.55
LT Debt/Eq —
EPS (ttm) -0.77
EPS next Y -0.72
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-13
ROA -35.09%
ROE -72.68%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 77.19M
Shs Float 64.94M
Insider Own 1.09%
Instit Own 59.23%
Short Float 9.79%
Short Ratio 4.48
Short Interest 7.55M
52W High 4.60
vs 52W High -16.52%
52W Low 1.35
vs 52W Low 184.44%
Beta 0.95
Impl. Vol. 37.50%
Rel Volume 0.60
Avg Volume 1.48M
Volume 895.01K
Target (mean) $8.20
Tgt Median $8.00
Tgt Low $5.00
Tgt High $12.00
# Analysts 5
Recom Strong_buy
Prev Close $3.58
Price $3.84
Change 7.26%
About

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.20
Mean price target
2. Current target
$3.84
Latest analyst target
3. DCF / Fair value
$-9.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.84
Low
$5.00
High
$12.00
Mean
$8.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-18 main Guggenheim Buy → Buy $8
2025-09-02 reit HC Wainwright & Co. Buy → Buy $9
2025-07-25 init Craig-Hallum — → Buy $12
2024-11-20 reit HC Wainwright & Co. Buy → Buy $16
2024-06-04 reit HC Wainwright & Co. Buy → Buy $16
2024-05-10 reit HC Wainwright & Co. Buy → Buy $16
2024-05-07 main HC Wainwright & Co. Buy → Buy $16
2024-03-22 reit HC Wainwright & Co. Buy → Buy $13
2023-11-13 reit HC Wainwright & Co. Buy → Buy $13
2023-10-24 main HC Wainwright & Co. Buy → Buy $13
2023-09-27 init Noble Capital Markets — → Outperform $10
2023-08-22 reit Cantor Fitzgerald Overweight → Overweight $9
2023-05-26 reit HC Wainwright & Co. Buy → Buy $25
2022-06-01 main SVB Leerink — → Outperform $26
2021-11-24 main HC Wainwright & Co. — → Buy $25
2021-04-27 main SVB Leerink — → Outperform $33
2021-03-23 init Cantor Fitzgerald — → Overweight $25
2021-02-08 init SVB Leerink — → Outperform $34
News
RSS: Latest ELDN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-09 KATKIN KEITH A Director — 8,575 — —
2026-01-09 MCBRIDE JOHN S Director — 3,430 — —
2026-01-09 LEE JUNE YONG Director — 3,430 — —
2026-01-09 ROBINSON JAMES A JR. Director — 3,430 — —
2026-01-09 HILLSON JAN M.D. PH.D. Director — 3,430 — —
2026-01-09 KIRK ALLAN Director — 3,430 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
83.25
+17.96%
70.58
+64.13%
43.00
+8.09%
39.78
Research And Development
66.27
+27.52%
51.96
+71.43%
30.31
+11.94%
27.08
Selling General And Administration
16.98
-8.75%
18.61
+46.70%
12.69
-0.09%
12.70
General And Administrative Expense
16.98
-8.75%
18.61
+46.70%
12.69
-0.09%
12.70
Salaries And Wages
9.74
-20.52%
12.26
—
—
Other Gand A
7.24
+13.96%
6.35
-49.92%
12.69
-0.09%
12.70
Total Expenses
83.25
+17.96%
70.58
+64.13%
43.00
+8.09%
39.78
Operating Income
-83.25
-17.96%
-70.58
-64.13%
-43.00
-8.09%
-39.78
Total Operating Income As Reported
—
—
-43.00
+51.37%
-88.43
EBITDA
-82.94
-18.12%
-70.22
-64.73%
-42.63
-8.17%
-39.41
Normalized EBITDA
-116.39
-15.10%
-101.12
-401.08%
33.59
+263.43%
9.24
Reconciled Depreciation
0.31
-12.81%
0.36
-4.01%
0.37
+0.27%
0.37
EBIT
-83.25
-17.96%
-70.58
-64.13%
-43.00
-8.09%
-39.78
Total Unusual Items
33.45
+8.25%
30.90
+140.55%
-76.21
-56.66%
-48.65
Total Unusual Items Excluding Goodwill
33.45
+8.25%
30.90
+140.55%
-76.21
-56.66%
-48.65
Special Income Charges
—
—
0.00
+100.00%
-48.65
Impairment Of Capital Assets
—
—
0.00
-100.00%
48.65
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Pretax Income
-45.58
-27.49%
-35.75
+69.32%
-116.54
-32.48%
-87.97
Net Non Operating Interest Income Expense
—
—
—
—
Net Interest Income
—
—
—
—
Other Income Expense
37.67
+8.17%
34.82
+147.36%
-73.54
-52.61%
-48.19
Other Non Operating Income Expenses
4.22
+7.54%
3.92
+46.75%
2.67
+478.79%
0.46
Gain On Sale Of Security
33.45
+8.25%
30.90
+140.55%
-76.21
—
Tax Provision
0.04
-91.88%
0.43
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
7.02
+8.25%
6.49
0.00
0.00
Net Income Including Noncontrolling Interests
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Net Income From Continuing Operation Net Minority Interest
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Net Income From Continuing And Discontinued Operation
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Net Income Continuous Operations
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Normalized Income
-72.04
-18.89%
-60.59
-50.26%
-40.33
-2.56%
-39.32
Net Income Common Stockholders
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Diluted EPS
-0.52
+21.21%
-0.66
+82.35%
-3.74
+39.29%
-6.16
Basic EPS
-0.52
+21.21%
-0.66
+82.35%
-3.74
+39.29%
-6.16
Basic Average Shares
81.84
+68.58%
48.54
+97.18%
24.62
+72.34%
14.29
Diluted Average Shares
81.84
+68.58%
48.54
+97.18%
24.62
+72.34%
14.29
Diluted NI Availto Com Stockholders
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
169.01
-4.73%
177.41
+99.18%
89.07
-4.02%
92.79
Current Assets
135.69
-5.60%
143.73
+156.07%
56.13
-5.69%
59.52
Cash Cash Equivalents And Short Term Investments
133.34
-4.88%
140.18
+174.31%
51.10
-9.41%
56.41
Cash And Cash Equivalents
22.81
+10.99%
20.55
+345.56%
4.61
-91.82%
56.41
Cash Equivalents
—
—
—
9.30
Cash Financial
—
—
—
47.11
Other Short Term Investments
110.53
-7.61%
119.63
+157.32%
46.49
0.00
Receivables
0.51
-17.76%
0.62
—
—
Accrued Interest Receivable
0.51
-17.76%
0.62
—
—
Prepaid Assets
1.83
-35.28%
2.82
-42.82%
4.94
+60.24%
3.08
Other Current Assets
0.01
-89.42%
0.10
+15.56%
0.09
+221.43%
0.03
Total Non Current Assets
33.32
-1.05%
33.67
+2.24%
32.94
-1.02%
33.27
Net PPE
0.61
-33.80%
0.93
+153.70%
0.36
-50.61%
0.74
Gross PPE
0.61
-33.80%
0.93
+153.70%
0.36
-50.61%
0.74
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.61
-33.80%
0.93
+153.70%
0.36
-50.61%
0.74
Other Properties
—
—
0.36
-50.61%
0.74
Goodwill And Other Intangible Assets
32.39
+0.00%
32.39
+0.00%
32.39
+0.00%
32.39
Goodwill
—
—
—
0.00
Other Intangible Assets
32.39
+0.00%
32.39
+0.00%
32.39
+0.00%
32.39
Other Non Current Assets
0.32
-11.29%
0.36
+95.16%
0.19
+24.00%
0.15
Total Liabilities Net Minority Interest
87.92
-23.52%
114.96
+40.44%
81.86
+850.73%
8.61
Current Liabilities
18.34
+58.45%
11.58
+197.23%
3.90
-39.85%
6.47
Payables And Accrued Expenses
13.81
+42.93%
9.66
+540.29%
1.51
-64.10%
4.20
Payables
3.63
-37.82%
5.83
+503.21%
0.97
-56.05%
2.20
Accounts Payable
3.63
-37.82%
5.83
+503.21%
0.97
-56.05%
2.20
Current Accrued Expenses
10.18
+165.94%
3.83
+606.46%
0.54
-72.94%
2.00
Pensionand Other Post Retirement Benefit Plans Current
4.18
+160.84%
1.60
-20.07%
2.00
+4.92%
1.91
Current Debt And Capital Lease Obligation
0.36
+14.01%
0.31
-18.02%
0.38
+5.51%
0.36
Current Capital Lease Obligation
0.36
+14.01%
0.31
-18.02%
0.38
+5.51%
0.36
Total Non Current Liabilities Net Minority Interest
69.58
-32.70%
103.38
+32.60%
77.96
+3551.66%
2.13
Long Term Debt And Capital Lease Obligation
0.28
-55.78%
0.64
0.00
-100.00%
0.38
Long Term Capital Lease Obligation
0.28
-55.78%
0.64
0.00
-100.00%
0.38
Non Current Deferred Liabilities
2.19
+0.18%
2.18
+24.60%
1.75
+0.00%
1.75
Non Current Deferred Taxes Liabilities
2.19
+0.18%
2.18
+24.60%
1.75
+0.00%
1.75
Preferred Securities Outside Stock Equity
55.69
+0.00%
55.69
—
—
Stockholders Equity
81.08
+29.85%
62.45
+766.34%
7.21
-91.44%
84.18
Common Stock Equity
81.08
+29.85%
62.45
+228.79%
-48.49
-157.60%
84.18
Capital Stock
0.07
+25.00%
0.06
-99.89%
55.72
+397885.71%
0.01
Common Stock
0.07
+25.00%
0.06
+150.00%
0.02
+71.43%
0.01
Preferred Stock
—
55.69
+0.00%
55.69
0.00
Share Issued
75.43
+26.16%
59.79
+146.93%
24.21
+75.75%
13.78
Ordinary Shares Number
75.43
+26.16%
59.79
+146.93%
24.21
+75.75%
13.78
Additional Paid In Capital
482.19
+15.37%
417.95
+54.29%
270.89
-5.62%
287.03
Retained Earnings
-401.20
-12.83%
-355.59
-11.33%
-319.40
-57.45%
-202.87
Gains Losses Not Affecting Retained Earnings
0.02
-7.69%
0.03
0.00
—
Other Equity Adjustments
0.02
-7.69%
0.03
—
—
Total Equity Gross Minority Interest
81.08
+29.85%
62.45
+766.34%
7.21
-91.44%
84.18
Total Capitalization
81.08
+29.85%
62.45
+766.34%
7.21
-91.44%
84.18
Working Capital
117.34
-11.21%
132.15
+153.00%
52.23
-1.53%
53.04
Invested Capital
81.08
+29.85%
62.45
+228.79%
-48.49
-157.60%
84.18
Total Debt
0.64
-32.81%
0.95
+149.09%
0.38
-48.66%
0.75
Capital Lease Obligations
0.64
-32.81%
0.95
+149.09%
0.38
-48.66%
0.75
Net Tangible Assets
48.70
+62.01%
30.06
+219.39%
-25.18
-148.61%
51.80
Tangible Book Value
48.70
+62.01%
30.06
+137.17%
-80.87
-256.13%
51.80
Derivative Product Liabilities
11.42
-74.55%
44.87
-41.13%
76.21
0.00
Preferred Stock Equity
—
55.69
+0.00%
55.69
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-62.34
-31.88%
-47.27
-19.59%
-39.53
-39.06%
-28.42
Cash Flow From Continuing Operating Activities
-62.34
-31.88%
-47.27
-19.59%
-39.53
-39.06%
-28.42
Net Income From Continuing Operations
-45.62
-26.07%
-36.18
+68.95%
-116.54
-32.48%
-87.97
Depreciation Amortization Depletion
0.31
-12.81%
0.36
-4.01%
0.37
+0.27%
0.37
Depreciation
0.31
-12.81%
0.36
-4.01%
0.37
+0.27%
0.37
Depreciation And Amortization
0.31
-12.81%
0.36
-4.01%
0.37
+0.27%
0.37
Other Non Cash Items
—
-0.01
—
—
Stock Based Compensation
10.45
-20.36%
13.12
+100.49%
6.54
-19.72%
8.15
Asset Impairment Charge
—
—
0.00
-100.00%
48.65
Deferred Tax
0.01
-98.84%
0.43
0.00
0.00
Deferred Income Tax
0.01
-98.84%
0.43
0.00
0.00
Operating Gains Losses
-33.45
-8.25%
-30.90
-140.55%
76.21
—
Gain Loss On Investment Securities
-33.45
-8.25%
-30.90
-140.55%
76.21
—
Change In Working Capital
7.65
-12.15%
8.71
+277.14%
-4.92
-307.64%
2.37
Change In Prepaid Assets
1.24
-4.39%
1.30
+166.43%
-1.95
-398.78%
0.65
Change In Payables And Accrued Expense
6.72
-13.25%
7.75
+398.12%
-2.60
-224.94%
2.08
Change In Payable
6.72
-13.25%
7.75
+398.12%
-2.60
-224.94%
2.08
Change In Account Payable
6.72
-13.25%
7.75
+398.12%
-2.60
-224.94%
2.08
Change In Other Current Liabilities
-0.31
+7.67%
-0.34
+6.61%
-0.36
+1.09%
-0.37
Investing Cash Flow
10.79
+115.35%
-70.31
-55.26%
-45.29
0.00
Cash Flow From Continuing Investing Activities
10.79
+115.35%
-70.31
-55.26%
-45.29
0.00
Net Investment Purchase And Sale
10.79
+115.35%
-70.31
-55.26%
-45.29
0.00
Purchase Of Investment
-161.13
-3.20%
-156.13
-99.43%
-78.29
0.00
Sale Of Investment
171.93
+100.34%
85.82
+160.05%
33.00
0.00
Net Business Purchase And Sale
—
—
—
—
Financing Cash Flow
53.81
-59.70%
133.52
+304.40%
33.02
0.00
Cash Flow From Continuing Financing Activities
53.81
-59.70%
133.52
+304.40%
33.02
0.00
Net Common Stock Issuance
53.58
-59.81%
133.31
+303.75%
33.02
0.00
Proceeds From Stock Option Exercised
0.23
+6.98%
0.21
0.00
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
2.26
-85.83%
15.94
+130.77%
-51.80
-82.23%
-28.42
Beginning Cash Position
20.55
+345.56%
4.61
-91.82%
56.41
-33.51%
84.83
End Cash Position
22.81
+10.99%
20.55
+345.56%
4.61
-91.82%
56.41
Free Cash Flow
-62.34
-31.88%
-47.27
-19.59%
-39.53
-39.06%
-28.42
Amortization Of Securities
-1.70
+39.41%
-2.80
-132.67%
-1.20
0.00
Common Stock Issuance
53.58
-59.81%
133.31
+303.75%
33.02
0.00
Issuance Of Capital Stock
53.58
-59.81%
133.31
+303.75%
33.02
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category